Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Clofarabine + Cyclophosphamide + Dasatinib + Etoposide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Clofarabine | Clolar | Clofarex | Clolar (clofarabine) is a purine nucleoside analog that inhibits ribonucleotide reductase and DNA polymerase, preventing DNA synthesis and repair, and induces apoptosis by inhibiting mitochondrial function (NCI Drug Dictionary). | |
Cyclophosphamide | Cytoxan | CPM | Chemotherapy - Alkylating 16 | Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary). |
Dasatinib | Sprycel | BMS-354825 | ABL Inhibitor (pan) 9 BCR-ABL Inhibitor 29 BTK inhibitor 34 CSF1R Inhibitor 28 DDR1 Inhibitor 9 DDR2 inhibitor 7 KIT Inhibitor 56 PDGFR Inhibitor (Pan) 28 SRC Inhibitor 31 TNK2 Inhibitor 6 | Sprycel (dasatinib) is an inhibitor of the SRC-family of protein kinases, BCR-ABL, and ABL, and has additional activity against other kinases including KIT, DDR1/2, PDGFRA/B, and EPHA2, which prevents cell growth (PMID: 25709401, PMID: 25284748, PMID: 18797457, PMID: 23942795). Sprycel (dasatinib) is FDA approved for both Philadelphia chromosome positive adult and pediatric chronic myelogenous leukemia and adult acute lymphoblastic leukemia (FDA.gov). |
Etoposide | Vepesid | EPEG|Eposin|VP-16|VP-16-213 | TOPO2 inhibitor 5 | Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|